| Title |
Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases
|
|---|---|
| Published in |
Clinical Pharmacology : Advances and Applications, October 2017
|
| DOI | 10.2147/cpaa.s138414 |
| Pubmed ID | |
| Authors |
Erwin Dreesen, Peter Bossuyt, Denis Mulleman, Ann Gils, Dora Pascual-Salcedo |
| Abstract |
Biopharmaceuticals directed against tumor necrosis factor-alpha, integrins, interleukins, interferons and their receptors have become key agents for the management of inflammatory diseases in the fields of gastroenterology, rheumatology, dermatology and neurology. However, response to these treatments is far from optimal. Therapeutic failure has been attributed in part to inadequate serum concentrations of the drug and the formation of antidrug antibodies (ADA). Therapeutic drug monitoring (TDM) based on drug concentrations and ADA represents a pharmacologically sound tool for guiding dosage adjustments to optimize exposure. Although becoming standard practice in tertiary care centers, the widespread accessibility and recognition of TDM is hindered by several hurdles, including a lack of education of health care providers on TDM. In this paper, the Monitoring of monoclonal Antibodies Group in Europe (MAGE) provides an introduction on the fundamental principles of the concept of TDM, aiming to educate clinicians and assist them in the process of implementing TDM of anti-inflammatory biopharmaceuticals. |
X Demographics
The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 4 | 50% |
| Venezuela, Bolivarian Republic of | 1 | 13% |
| France | 1 | 13% |
| Unknown | 2 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 5 | 63% |
| Practitioners (doctors, other healthcare professionals) | 3 | 38% |
Mendeley readers
The data shown below were compiled from readership statistics for 112 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 112 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 19 | 17% |
| Researcher | 15 | 13% |
| Student > Ph. D. Student | 14 | 13% |
| Student > Doctoral Student | 9 | 8% |
| Other | 8 | 7% |
| Other | 22 | 20% |
| Unknown | 25 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 26 | 23% |
| Pharmacology, Toxicology and Pharmaceutical Science | 21 | 19% |
| Agricultural and Biological Sciences | 6 | 5% |
| Nursing and Health Professions | 5 | 4% |
| Immunology and Microbiology | 5 | 4% |
| Other | 18 | 16% |
| Unknown | 31 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 April 2018.
All research outputs
#4,537,346
of 25,382,440 outputs
Outputs from Clinical Pharmacology : Advances and Applications
#44
of 179 outputs
Outputs of similar age
#74,226
of 331,218 outputs
Outputs of similar age from Clinical Pharmacology : Advances and Applications
#2
of 5 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. Compared to these this one has done well and is in the 82nd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 179 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.8. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 331,218 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 77% of its contemporaries.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.